The one-quarter rule, and the paper that took it apart

For roughly forty years, clinical teaching held that about a quarter of the mass lost during weight reduction is fat-free tissue. It is a serviceable average and it has been treated as a constant, which it is not: the fraction depends on the starting adiposity, the rate of loss, the protein intake, the activity pattern and the duration, and it varies across studies from well under a fifth to well over a third. A critical review a decade ago traced the rule to a small number of older studies and concluded that its use as a fixed expectation was unsupportable. The rule is still quoted as though nothing had happened.

The one-quarter rule and the paper that dismantled it

Clinical teaching has long held that approximately twenty-five per cent of the mass lost during weight reduction is fat-free tissue. The figure appears in textbooks, in review articles and in a great deal of consumer material, usually without a citation and always without an interval.

A critical review published in 2014 traced the rule to a limited number of older studies, examined the variation across the wider literature, and concluded that treating one-quarter as a constant is not defensible.¹ The fraction of loss that is fat-free tissue varies systematically with baseline adiposity — heavier people lose proportionally more fat — and with the rate of loss, the protein intake, the activity pattern and the measurement method. Reported values span from well under fifteen per cent to above thirty-five.

This matters for the current argument in a specific way. Both the reassuring and the alarming readings of the incretin substudy data are constructed by comparing an observed fat-free fraction against the one-quarter benchmark. If the benchmark is a loose average rather than an expectation, both comparisons are weaker than they appear, and the honest statement is that the observed fractions sit within the range that dietary weight loss has always produced.

Proportion of loss against absolute kilograms

There is a rhetorical move available to both sides of this argument and it works by choosing a denominator. Report lean mass as a proportion of total body mass and it rises during successful treatment, because fat is falling faster; the treatment looks composition-improving, which it is. Report lean mass in absolute kilograms and it falls; the treatment looks muscle-costing, which it also is. Both statements can be made from the same scan pair without either being false.

The Journal reports both, in that order, and thinks anybody presenting only one should be asked why. The proportional figure is the right one for questions about metabolic quality: a body with a higher lean fraction handles glucose better and carries less ectopic fat. The absolute figure is the right one for questions about function and reserve, because a hip fracture at seventy-eight is not prevented by a favourable ratio.

The two framings also diverge most sharply exactly where the stakes are highest. A person losing twenty-five per cent of their body weight will show an excellent proportional result and the largest absolute lean-mass reduction in the cohort. Selecting the framing selects the conclusion, which is why the trade has settled on whichever one suits it.

The prescription survives scrutiny; the reasoning often does not

Two claims are routinely bundled together and only one is well supported. The weaker claim is that resistance training during pharmacological weight loss builds or maintains muscle mass. In a substantial energy deficit, training generally attenuates the loss rather than preventing it, and net accrual is unusual outside of untrained beginners and the specific controlled-feeding conditions of the trials cited earlier. The stronger claim is that training preserves strength and physical function even where mass declines, which is consistently observed and is mechanistically sensible: a large part of early strength change is neural rather than structural.

The distinction has practical consequences. Somebody training hard, eating well, and watching their DXA appendicular lean mass fall by two kilograms across nine months has not failed at anything, and may be measurably stronger than at baseline. If the expectation set for them was mass preservation, they will read a normal outcome as a failure and may respond by eating more or training in ways that suit the metric rather than the goal.

The Journal reports the training recommendation and reports what it is expected to achieve, which is function first and mass second.

Sarcopenia is a diagnosis, not a synonym

The word sarcopenia has migrated from clinical medicine into consumer discussion of this drug class and lost its definition in transit. In the working definitions used by the European and Asian consensus groups, sarcopenia requires low muscle strength, with low muscle quantity or quality confirming it and poor physical performance indicating severity. Strength is the entry criterion. Reduced lean mass on a scan, in the absence of measured weakness, does not meet any published definition of sarcopenia.

This matters because the borrowed term imports a prognosis. Sarcopenia in its clinical sense is associated with falls, fractures, hospitalisation and mortality, and those associations were established in older adults with measured weakness, frequently in the context of illness or immobility. Applying the label to a forty-two-year-old whose DXA appendicular lean mass has fallen by one and a half kilograms while their strength has increased is not a cautious extrapolation; it is a category error with a frightening prognosis attached.

The related term sarcopenic obesity has the same problem in a more acute form, since it requires both criteria to be met and is frequently used to mean nothing more than a low lean fraction. The Journal uses both terms only in their defined sense and asks correspondents who use them to say which criteria they mean.

On the phrase "muscle-sparing"

Two commercial claims have attached themselves to this subject and both deserve naming. The first is that a particular agent in the class is muscle-sparing relative to the others. No head-to-head trial has compared body composition between agents in this class, at matched weight loss or otherwise. Cross-trial comparison of DXA substudies with different populations, durations, scanners and analysis definitions cannot support a ranking, and every published ranking of that kind is an artefact of the comparison rather than a finding.

The second is that a supplement, peptide or co-administered compound preserves lean mass during incretin treatment. The Journal has reviewed the material behind several such claims and found the same structure each time: a mechanistic rationale, a small study in a different population or in animals, and no randomised evidence in anybody taking a GLP-1 receptor agonist. Several of the compounds marketed for this purpose are sold for research use only and are not approved for human use in any jurisdiction, a fact that the marketing generally states in small type and contradicts in large.

Neither claim is refuted. Both are unevidenced, which in a market this size is the more useful thing to establish.

The next instalment in this department takes up the question that follows this one chronologically rather than logically: what happens to all of it when treatment stops. The composition of regained weight is a separate literature, it is thinner than this one, and what little exists is not encouraging.